| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
5,527 |
5,090 |
$1.40M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
8,161 |
7,803 |
$1.26M |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
1,649 |
1,606 |
$204K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
5,133 |
4,954 |
$94K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,598 |
2,532 |
$94K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,485 |
1,324 |
$85K |
| 71045 |
Radiologic examination, chest; single view |
1,396 |
1,299 |
$70K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
11,818 |
10,316 |
$67K |
| 86901 |
|
516 |
465 |
$66K |
| 80053 |
Comprehensive metabolic panel |
7,291 |
6,294 |
$46K |
| 86900 |
|
491 |
465 |
$44K |
| 87806 |
|
1,302 |
1,268 |
$42K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
726 |
568 |
$36K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
564 |
547 |
$36K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
986 |
956 |
$35K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
619 |
529 |
$23K |
| 87088 |
|
3,043 |
2,829 |
$20K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
128 |
118 |
$19K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,559 |
1,509 |
$15K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
82 |
79 |
$14K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
365 |
355 |
$13K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
363 |
354 |
$13K |
| 81001 |
|
5,041 |
4,616 |
$12K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
83 |
77 |
$12K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,062 |
877 |
$12K |
| 83880 |
|
1,250 |
1,096 |
$11K |
| 86885 |
|
1,543 |
1,479 |
$9K |
| 70450 |
Computed tomography, head or brain; without contrast material |
214 |
203 |
$8K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
961 |
846 |
$8K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
575 |
559 |
$7K |
| 80061 |
Lipid panel |
1,546 |
1,503 |
$7K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
89 |
86 |
$7K |
| 86592 |
|
1,463 |
1,408 |
$6K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,485 |
1,452 |
$6K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,194 |
1,152 |
$5K |
| 87340 |
|
430 |
410 |
$4K |
| 84484 |
|
1,197 |
955 |
$4K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
51 |
51 |
$4K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
249 |
222 |
$3K |
| 86762 |
|
259 |
247 |
$3K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
27 |
26 |
$3K |
| 81025 |
|
333 |
319 |
$3K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
53 |
53 |
$3K |
| 84439 |
|
309 |
301 |
$3K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,116 |
924 |
$3K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
20 |
18 |
$3K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
157 |
152 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
584 |
495 |
$2K |
| 87653 |
|
54 |
52 |
$2K |
| 87077 |
|
610 |
571 |
$2K |
| 87186 |
|
568 |
532 |
$2K |
| 83690 |
|
634 |
560 |
$2K |
| 85610 |
|
856 |
771 |
$2K |
| 85730 |
|
695 |
662 |
$2K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
16 |
16 |
$2K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
304 |
286 |
$1K |
| 82947 |
|
564 |
369 |
$1K |
| CP008 |
|
29 |
26 |
$1K |
| 82553 |
|
391 |
324 |
$1K |
| 83735 |
|
423 |
377 |
$1K |
| 71046 |
Radiologic examination, chest; 2 views |
38 |
37 |
$919.55 |
| 82550 |
|
583 |
475 |
$910.63 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
46 |
45 |
$879.33 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
736 |
640 |
$843.65 |
| 36415 |
Collection of venous blood by venipuncture |
16,551 |
13,532 |
$806.59 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
142 |
134 |
$622.13 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
29 |
28 |
$565.80 |
| 87040 |
|
84 |
53 |
$461.72 |
| 83655 |
|
24 |
24 |
$343.35 |
| 84702 |
|
16 |
12 |
$321.54 |
| 83605 |
|
82 |
64 |
$284.37 |
| 82950 |
|
40 |
39 |
$213.96 |
| 84703 |
|
27 |
24 |
$189.26 |
| 86787 |
|
12 |
12 |
$167.76 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
172 |
133 |
$108.96 |
| 82607 |
|
17 |
16 |
$44.10 |
| 82728 |
|
17 |
17 |
$39.84 |
| 82746 |
|
16 |
15 |
$21.49 |
| 83550 |
|
16 |
16 |
$12.77 |
| 85652 |
|
12 |
12 |
$10.32 |
| 83540 |
|
34 |
32 |
$9.45 |
| P9604 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge |
1,208 |
926 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
28 |
27 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
12 |
12 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
12 |
12 |
$0.00 |